2023 ESMO前瞻｜消化系統腫瘤重磅研究一覽！

2023年歐洲腫瘤內科學會（ESMO）年會將于10月20日-24日在西班牙馬德里召開。ESMO大會涵蓋基礎研究、轉化研究以及最新臨床研究進展，將為臨床實踐、多學科討論等提供廣闊、卓越的學術平臺。醫脈通編輯特整理消化系統腫瘤重磅研究如下，以饗讀者。

日期：2023年10月21日，星期六

時間：14:45 – 16:15

主席：Chiara Cremolini (Pisa, Italy) ,Rodrigo Dienstmann (Sao Paulo, Brazil)

地點：Sevilla Auditorium – Hall 9

標題：Neoadjuvant short-course radiotherapy followed by camrelizumab plus chemotherapy versus long-course chemoradiotherapy followed by chemotherapy in locally advanced rectal cancer: a randomized phase III trial (UNION)

報告人：林振宇（華中科技大學附屬協和醫院）

時間：14:45 – 14:55

標題：Neoadjuvant Chemotherapy with CAPOX versus Chemoradiation for Locally Advanced Rectal Cancer with Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial

報告人：丁培榮（中山大學腫瘤防治中心）

時間：14:55 – 15:05

標題：Adagrasib With or Without Cetuximab in Patients With KRASG12C-Mutated Colorectal Cancer (CRC): Analysis of Tumor Biomarkers and Genomic Alterations

報告人：Meredith S. Pelster（Nashville, United States of America）

時間：15:25 – 15:35

標題：Safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC): a phase II study

報告人：徐瑞華（中山大學腫瘤防治中心）

時間：15:35 – 15:45

標題：First-line systemic treatment in patients with initially unresectable colorectal cancer liver metastases (CRLM): overall survival of the phase III CAIRO5 study of the Dutch Colorectal Cancer Group

報告人：Cornelis J. Punt（Utrecht, Netherlands）

時間：08:40 – 08:50

標題：The PEGASUS trial: post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients

報告人：Sara Lonardi（Padova, Italy）

時間：09:10 – 09:20

標題：Aspirin After Standard Adjuvant Therapy for Colorectal Cancers (ASCOLT) – An International, Phase III, Randomised, Placebo-controlled Trial

報告人：John W. Chia （Singapore, Singapore）

時間：09:20 – 09:30

標題：FOxTROT: results of embedded phase II evaluating the addition of panitumumab (pan) to neo-adjuvant FOLFOX for patients (pts) with KRAS-wt colon cancer (CC) with extended biomarker panel

報告人：Jenny Seligmann（Leeds, United Kingdom）

時間：08:30 – 08:40

日期：2023年10月22日，星期日

時間：14:45 – 16:20

主席：Gunnar Folprecht (Dresden, Germany), Raghav Sundar (Singapore, Singapore), Jeanne Tie (Melbourne, Australia)

地點：Burgos Auditorium – Hall 3

標題：Panitumumab (P) + FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer (mCRC) patients (pts) with RAS/BRAF wild-type (WT) tumor status from circulating DNA (cirDNA). First results of the randomised phase II PANIRINOX-UCGI28 study

報告人：Thibault Mazard（Montpellier, Cedex 5, France）

時間：14:45 – 14:50

標題：Neoadjuvant nivolumab plus relatlimab (anti-LAG3) in locally advanced MMR-deficient colon cancers: the NICHE-3 study

報告人：Yara L. Verschoor（Amsterdam, Netherlands）

時間：15:15 – 15:20

標題：Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase 3 KEYNOTE-177 study

報告人：Kai-Keen Shiu（London, United Kingdom）

時間：15:25 – 15:30

標題：Cetuximab Plus FOLFOXIRI Versus Cetuximab Plus FOLFOX as conversion therapy in RAS Wild-type Patients with Initially Unresectable Colorectal Liver

報告人：李宇紅（中山大學腫瘤防治中心）

時間：14:50 – 14:55

標題：Modified (m)-FOLFOXIRI plus cetuximab treatment and predictive clinical factors for RAS/BRAF wild-type and left-sided metastatic colorectal cancer (mCRC): the DEEPER trial (JACCRO CC-13)

報告人：Yu Sunakawa（Kawasaki, Japan）

時間：14:55 – 15:00

標題：A phase II clinical trial of sintilimab plus chidamide combined with or without bevacizumab in patients with MSS/pMMR metastatic colorectal cancer

報告人：王峰（中山大學腫瘤防治中心）

時間：15:20 – 15:25

標題：Circulating tumor (ct)DNA as a prognostic biomarker in patients (pts) with resected colorectal cancer (CRC): an updated 24 months (mos) disease free survival (DFS) analysis from GALAXY study (CIRCULATE-Japan)

報告人：Yoshiaki Nakamura（Kashiwa, Japan）

時間：15:50 – 15:55

日期：2023年10月20日，星期五

時間：14:45 – 16:15

主席：G?ran J?nsson (Lund, Sweden)

地點：Santander Auditorium – Hall 9

標題：Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): interim results of the global, Phase 3 MATTERHORN study

時間：14:10 – 14:20

標題：Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The Phase 3 KEYNOTE-585 study

報告人：Kohei Shitara（Kashiwa, Japan）

時間：14:00 – 14:10

標題：Pembrolizumab plus Trastuzumab and Chemotherapy for HER2+ Metastatic Gastric or Gastroesophageal Junction (mG/GEJ) Adenocarcinoma: Survival results from the Phase 3, Randomized, Double-blind, Placebo-controlled KEYNOTE-811 Study

報告人：Yelena Y. Janjigian（New York, United States of America）

時間：15:10 – 15:20

日期：2023年10月22日，星期日

時間：10:15 – 11:45

地點：Barcelona Auditorium – Hall 9

標題：The primary results of an intergroup phase III randomized controlled trial comparing ramucirumab plus irinotecan with irinotecan in the third or later line treatment beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG Trial).

報告人：Shigenori Kadowaki（Nagoya, Japan）

時間：11:05 – 11:15

標題：Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): a multicenter randomized controlled trial

報告人：Bas Groot Koerkamp（Rotterdam, Netherlands）

時間：10:25 – 10:35

標題：Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): a multicenter, randomized, open-label, three-arm, phase 2/3 trial

報告人：Akihiro Ohba（Chuo-ku, Japan）

時間：10:15 – 10:25

日期：2023年10月21日，星期六

時間：16:30 – 18:10

主席：Lorenza Rimassa (Rozzano, Italy), Tania C. Fleitas (Valencia, Spain)

地點：Bilbao Auditorium – NCC

標題：Overall Survival of Perioperative or Postoperative Adjuvant Oxaliplatin with S-1 versus Adjuvant Oxaliplatin with Capecitabine in Locally Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma Undergoing D2 Gastrectomy: An Updated Analysis of RESOLVE Trial

報告人：張小田（北京大學腫瘤醫院）

時間：17:00 – 17:05

標題：GEMSTONE-303: prespecified progression-free survival (PFS) and overall survival (OS) final analyses of a phase 3 study of sugemalimab plus chemotherapy vs placebo plus chemotherapy in treatment-na?ve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma

報告人：張小田（北京大學腫瘤醫院）

時間：17:20 – 17:25

標題：Tislelizumab (TIS) Plus Chemotherapy (Chemo) vs Placebo (PBO) Plus Chemo as First-Line (1L) Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (GC/GEJC): Final Analysis Results of the RATIONALE-305 Study

報告人：徐瑞華（中山大學腫瘤醫院）

時間：17:25 – 17:30

標題：Updated efficacy and safety results from phase 3 GLOW study evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2?, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma

報告人：Florian Lordick（Leipzig, Germany）

時間：17:50 – 17:55

標題：Updated efficacy and safety results from phase 3 SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2?, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma

報告人：Jaffer A. Ajani（Houston, United States of America）

時間：17:55 – 18:00

標題：Tinengotinib in Patients with Advanced, Fibroblast Growth Factor Receptor (FGFR) inhibitor Refractory/Relapsed Cholangiocarcinoma

報告人：Meredith S. Pelster（Nashville, United States of America）

時間：16:40 – 16:45

標題：AdvanTIG-206: Phase 2 Randomized Open-Label Study of Ociperlimab (OCI) + Tislelizumab (TIS) + BAT1706 (Bevacizumab Biosimilar) Versus TIS + BAT1706 in Patients (pts) With Advanced Hepatocellular Carcinoma (HCC)

報告人：Ming Mo Hou (桃園，中國臺灣)

時間：16:30 – 16:35

標題：Perioperative camrelizumab (C) combined with rivoceranib (R) and chemotherapy (chemo) versus chemo for locally advanced resectable gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: the first interim analysis of a randomized, phase 3 trial (DRAGON IV)

報告人：陳立（上海交通大學醫學院附屬瑞金醫院）

時間：17:00 – 17:05

標題：A Phase II study of Nivolumab plus low dose Ipilimumab as 1st line therapy in patients with advanced gastric or esophago-gastric junction MSI-H tumor: First results of the NO LIMIT study (WJOG13320G/CA209-7W7)

報告人：Kei Muro（Nagoya, Japan）

時間：17:30 – 17:35

日期：2023年10月23日，星期一

時間：10:15 – 11:40

主席：Gary Middleton (Birmingham, United Kingdom), Alessandra Curioni-Fontecedro (Villar sur Glane, Switzerland)

地點：Burgos Auditorium – Hall 3

標題：Phase I Study of GCC CAR-T therapy IM96 in Patients With Advanced Colorectal Cancer

報告人：齊長松 (北京大學腫瘤醫院)

時間：10:55 – 11:05

日期：2023年10月21日，星期六

時間：16:30 – 17:50

主席：Alessandra Curioni-Fontecedro (Villar sur Glane, Switzerland), María José De Miguel (Madrid, Spain)

地點：Málaga Auditorium – Hall 10

標題：AdvanTIG-203: Phase 2 Randomized, Multicenter Study of Ociperlimab (OCI) + Tislelizumab (TIS) in Patients (pts) With Unresectable, Locally Advanced, Recurrent/Metastatic Esophageal Squamous Cell Carcinoma (ESCC) and Programmed Cell Death-Ligand 1 (PD--L1) Positivity

報告人：王峰 (中山大學腫瘤防治中心)

時間：16:30 – 16:35